Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

The Role of CELMoD Agents in Multiple Myeloma.

View Full Paper
Ask AI
Bookmark
Share

Authors

NDNiels W.C.J. van de DonkNBNizar J. BahlisCPCharlotte Pawlyn

Discussion

Loading...

Member takes

Overview

Observational analysis shows CELMoD agents improve outcomes in relapsed or refractory multiple myeloma, suggesting new treatment options.

Key Points

  • Iberdomide and mezigdomide may improve outcomes for multiple myeloma patients who are refractory to standard treatments.
  • Preclinical data indicate iberdomide and mezigdomide provide potential therapeutic benefits, supporting their evaluation as treatments.
  • The optimized potency and safety profiles of these CELMoD agents suggest their suitability for clinical use in multiple myeloma patients.
  • Both iberdomide and mezigdomide are currently under evaluation in trials, with early results indicating promising efficacy.

Cite This Study

Donk et al. (2025) studied this question.

synapsesocial.com/papers/68c18f2a9b7b07f3a06154fchttps://doi.org/10.2147/ott.s398118
View Full Paper
Ask AI
Bookmark
Share